✦ LIBER ✦

A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer

✍ Scribed by Suleiman Massarweh; Yee L. Tham; Jian Huang; Krystal Sexton; Heidi Weiss; Anna Tsimelzon; Amanda Beyer; Mothaffar Rimawi; Wei Yen Cai; Susan Hilsenbeck; Suzanne Fuqua; Richard Elledge

Publisher: Springer US
Year: 2011
Tongue: English
Weight: 361 KB
Volume: 129
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-011-1679-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effect of adding gefitinib to neoadjuvan

Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial

✍ Mogens Bernsdorf; Christian Ingvar; Leif Jörgensen; Malgorzata K. Tuxen; Erik H. 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 209 KB

Phase 2 randomized trial of primary endo

Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer

✍ Vladimir F. Semiglazov; Vladislav V. Semiglazov; Garik A. Dashyan; Elena K. Zilt 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 194 KB

## Abstract ## BACKGROUND. Few studies have compared primary neoadjuvant endocrine therapy with neoadjuvant chemotherapy in breast cancer patients. The need for preoperative chemotherapy with doxorubicin or taxanes may be reduced in postmenopausal patients with estrogen receptor (ER)‐positive and/

A randomized trial exploring the biomark

A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer

✍ O. C. Freedman; E. Amir; W. Hanna; H. Kahn; F. O’Malley; G. Dranitsaris; D. E. C 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 257 KB

A phase I/II prospective, single arm tri

A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer

✍ G. Somlo; C. L. Martel; S. K. Lau; P. Frankel; C. Ruel; L. Gu; A. Hurria; C. Chu 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 229 KB

Exemestane versus anastrozole as front-l

Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer : Final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial

✍ Antonio Llombart-Cussac; Amparo Ruiz; Antonio Antón; Agustí Barnadas; Silvia Ant 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 2 views

Phase I/II dose escalation study of angi

Phase I/II dose escalation study of angiotensin 1-7 [A(1-7)] administered before and after chemotherapy in patients with newly diagnosed breast cancer

✍ Kathleen E. Rodgers; Jamie Oliver; Gere S. diZerega 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 337 KB